Experiences and perspectives on the GIST patient journey

PURPOSE: The tyrosine kinase inhibitor (TKI) imatinib has improved outcomes for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST), and for patients receiving adjuvant therapy following GIST resection. This qualitative study explored the experiences and emotions of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdonald, Nancy, Shapiro, Ari, Bender, Christina, Paolantonio, Marc, Coombs, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333816/
https://www.ncbi.nlm.nih.gov/pubmed/22536061
http://dx.doi.org/10.2147/PPA.S24617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333816/
https://www.ncbi.nlm.nih.gov/pubmed/22536061
http://dx.doi.org/10.2147/PPA.S24617

Ejemplares similares